LDS/Medical Tests/Felbamate, Urine

Felbamate, Urine

Felbamate is classified as an anticonvulsant drug and used to treat epileptic seizures. The class of drugs known as anticonvulsants are designed to help the physician in treating patients with seizures. The most common type of seizure that the physician encounters in clinical medicine are epileptic seizures. Basically a seizure is an abnormal, excessive firing of neurons in the gray matter of the brain. Epilepsy is a disease of the brain in which an individual experiences recurrent seizures. Children may develop seizures as a result of a fever, known as febrile seizures.

The specific type of seizures that felbamate is used to treat are partial seizures with or without generalization, and to treat the same in Lennox-Gastaut syndrome in children. Felbamate is metabolized via the cytochrome P450 system in the liver, but is really not metabolized to any extent to active metabolites, allowing the parent drug to be the only drug appreciably detected in the urine.

As with most therapeutic drugs, felbamate is metabolized in the liver but absorbed mainly in the small intestine. The route of administration of felbamate is orally. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. Felbamate can be analyzed by a variety of analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay, and screening spot testing.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of felbamate and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic level: 30-60 mg/L

Toxic level: > 120 mg/L     

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.    

 

Cut-Off Ranges

Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to not only detect the parent drug, felbamate, but also the major metabolites. Felbamate can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. Felbamate is not extensively bound to protein and usually appear in the urine as the glucuronide conjugate. When analyzing urine specimens a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Serum

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.

Stability

  • Refrigeration: 14 days
  • Frozen: 14 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19, COMT* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Lettleton, MA: PSG Publisging Co.; 1987
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatogr. 1985;340:139-72.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 22, Anticonvulants and Antiarrhythmics, pp. 391-402; 2013.